The current lawsuits were consolidated on October 15th, 2015 to form multidistrict litigation no. 2656 before the Honorable Judge F. Dennis Saylor, United States District for the Eastern District of Pennsylvania. The recent MDL consolidation is a win for Plaintiffs, allowing strengthened discovery while it is still early in the litigation process.
Zofran was initially approved by the FDA to treat patients dealing with extreme bouts of nausea and vomiting after undergoing chemotherapy, radiation therapy, or anesthesia. Although never approved for pregnancies, GlaxoSmithKline nonetheless marketed the drug to Ob/Gyns and pregnant women for morning sickness.
Now, many parents are claiming Zofran caused birth defects in their children that could have been avoided had Zofran been properly marketed.
Zofran is estimated to to have been prescribed to over 1 million pregnant women annually. Plaintiffs are alleging a connection between Zofran and babies born with serious and sometimes even life-threatening defects. These defects most commonly include cleft palate, cleft lip, and congenital heart defects.
Now that the MDL has been established, it is important for families to know that the sooner they review and file their claims the better. For additional information, please contact: